Dr. Weber is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
160 East 34th Street
7th Floor
New York, NY 10016- Is this information wrong?
Education & Training
- National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1985 - 1988
- University of California (San Diego) Medical CenterInternship, Internal Medicine, 1980 - 1981
- New York University School of MedicineClass of 1980
Certifications & Licensure
- CA State Medical License 1994 - Present
- NY State Medical License 1983 - 2025
- FL State Medical License 2007 - 2017
- MD State Medical License 1985 - 1995
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Phase I/II Study of Dasatinib and Dacarbazine Start of enrollment: 2007 Nov 01
- Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma Start of enrollment: 2009 Jan 23
- Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100 Start of enrollment: 2009 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- 5 citationsIndividualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.Weber, J., Carlino, M., Khattak, A., Meniawy, T., Ansstas, G., Taylor, M., Kim, K., McKean, M., Long, G., Sullivan, R., Faries, M., Tran, T., Cowey, C., Pecora, A., Sh...> ;Lancet. 2024 Feb 17
- Linear IgA bullous dermatosis induced by nemvaleukin alfa, an engineered interleukin 2 molecule, in a patient with treatment-refractory metastatic melanoma.Fatima Bawany, Vignesh Ramachandran, Eduardo Rodriguez, Randie H Kim, Jeffrey S Weber, Ian W Tattersall> ;JAAD Case Reports. 2023 Nov 1
- 11 citationsSystemic Therapy for Melanoma: ASCO Guideline Update.Rahul Seth, Sanjiv S Agarwala, Hans Messersmith, Krishna C Alluri, Paolo A Ascierto, Michael B Atkins, Kathryn Bollin, Matias Chacon, Nancy Davis, Mark B Faries, Pauli...> ;Journal of Clinical Oncology. 2023 Oct 20
- Join now to see all
Journal Articles
- The Society for Immunotherapy of Cancer Perspective on Regulation of Interleukin-6 Signaling in COVID-19-Related Systemic Inflammatory ResponseSteven J O'Day, Walter J Urba, Jeffrey S Weber, Journal For Immunotherapy of Cancer
Lectures
- Serum IL-6 and CRP as prognostic factors in melanoma patients receiving single agent and combination checkpoint inhibition.2019 ASCO Annual Meeting - 6/1/2019
- Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238).2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Press Mentions
- NYU Langone Health in the News—Monday, May 8, 2023May 8th, 2023
- Personalized mRNA Vaccine Boosts Immunotherapy for High-Risk MelanomaApril 19th, 2023
- Merck’s Keytruda Scores Triple Hit at AACRApril 19th, 2023
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
- NYU Langone HospitalsNew York, New York
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: